# Tian'an Technology Group Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Tian'an Technology Group Ltd). ## Overview Tian'an Technology Group Ltd is a holding company whose operating activities are carried out through subsidiaries in Hong Kong and mainland China. Its business centers on healthcare-related products and services, including graphene-based far-infrared heat therapy products, healthcare product sales, and healthcare service development in China. ## Products & services • Graphene-based far-infrared heat therapy products • Healthcare product sales • Healthcare services • AI software development for healthcare applications • Online medicine distribution platform development - **Graphene health therapy products** (35%) — Graphene-enabled products that use far-infrared heat therapy properties. - **Healthcare product sales** (30%) — Sale of healthcare-related products through operating subsidiaries. - **Healthcare services** (20%) — Healthcare service offerings provided through the Henan subsidiary. - **Healthcare technology and software** (10%) — AI software development and related digital healthcare capabilities. - **Online medicine distribution platform** (5%) — Planned digital platform for medication delivery to customers. - Graphene-based far-infrared heat therapy products - Healthcare product sales - Healthcare services - AI software development for healthcare applications - Online medicine distribution platform development ## Customers The company serves customers in the healthcare and wellness market, with initial marketing efforts focused on Eastern China. Its products and services are aimed at buyers seeking graphene-based therapy products, healthcare goods, and access to healthcare services. The planned medicine distribution platform also points to end users needing more convenient medication delivery. - **Health and wellness consumers** (primary) — Buy graphene-based far-infrared therapy products for personal wellness use. - **Healthcare product buyers** (primary) — Purchase healthcare-related products sold through Shanghai Qige and Tian'an HK. - **Healthcare service users** (secondary) — Use healthcare services offered through Henan Qige in China. - **Digital pharmacy users** (emerging) — Use the planned online medicine distribution channel for medication delivery. - Health and wellness consumers buying therapy-oriented products - Customers seeking healthcare products in Eastern China - Patients and users of healthcare services in China - Buyers needing convenient medication delivery - Potential customers for digital healthcare offerings ## Geography The company is organized across the British Virgin Islands, Hong Kong, and mainland China, but its operating business is primarily conducted in the PRC. Management has said initial marketing is concentrated in Eastern China, with plans to build a nationwide network over time. This makes mainland China the core commercial market and also the main source of regulatory and operating exposure. - **China** (100%) — Operating activities are primarily conducted in the PRC. - Operations are primarily conducted in mainland China - Initial marketing is focused on Eastern China - Hong Kong subsidiary supports sales and holding activities - PRC subsidiaries carry most operating activity - Business exposure is concentrated in China regulatory conditions ## Strategy The company is building a healthcare-focused business around graphene therapy products, healthcare services, and related digital distribution capabilities. Its stated priorities include expanding from Eastern China toward a broader national marketing footprint and adding adjacent healthcare service and software offerings to deepen its market reach. - **Expand healthcare and graphene product portfolio** (short-term) — It broadens the company's addressable market beyond a single product concept. - **Build healthcare services capability** (medium-term) — Services can create recurring customer relationships and diversify the business mix. - **Develop digital distribution channels** (medium-term) — An online medicine platform can support broader customer access and convenience. - **Expand from regional to national marketing** (medium-term) — A wider sales network is needed to scale beyond the Eastern China launch area. - Expand graphene-based health therapy offerings - Develop healthcare services through Henan Qige - Build an online medicine distribution platform - Broaden marketing from Eastern China to nationwide - Increase sales activity through Hong Kong and PRC subsidiaries ## Risks The business is exposed to China operating, regulatory, and currency-related risks because substantially all operations are conducted in the PRC. It also faces execution risk as it moves from product sales into healthcare services, AI software, and online distribution, which require different capabilities, compliance standards, and customer adoption. - **PRC regulatory and policy risk** [high] — Operations are primarily conducted in China, so changes in laws or policy can directly affect sales and services. - **Foreign exchange and remittance restrictions** [medium] — The company reports in USD but operates principally in RMB and HKD, creating translation and transfer risk. - **Execution risk in new healthcare initiatives** [high] — The company is extending from product sales into healthcare services, AI software, and online pharmacy distribution. - **Customer demand and market acceptance risk** [medium] — Graphene therapy products and related health offerings depend on customer adoption and perceived efficacy. - PRC regulatory changes could affect healthcare and product sales - China operating exposure creates currency and remittance risk - Healthcare expansion requires compliance and service execution - New product and platform adoption may be uncertain - Holding-company structure can concentrate operational dependence in subsidiaries ## Accounting The company consolidates multiple subsidiaries across BVI, Hong Kong, and the PRC, so intercompany eliminations and related-party balances are important to interpret. Because the business operates in RMB and HKD but reports in USD, translation effects and cash movement between entities can affect reported balances. Investors should also watch how healthcare product sales, service revenue, and any platform-related revenue are recognized as the business model evolves. - **Foreign currency translation** — Can move reported assets, liabilities, and results without cash change. - **Related-party balances** — Affects liquidity analysis and must be understood in consolidation context. - **Revenue recognition across business lines** — Timing and classification of revenue may differ by activity. - **Cash and restricted cash classification** — Affects liquidity interpretation and available working capital. - USD reporting currency with RMB/HKD functional currencies - Consolidation eliminates intercompany balances and transactions - Related-party payables are material and need scrutiny - Revenue recognition may differ across products, services, and platform sales - Cash balances are held in PRC institutions and exposed to deposit risk --- *Last updated: 2026-09-28T12:18:28.253455+00:00*